LBA53 Alliance A021602: Phase III, double-blinded study of cabozantinib versus placebo for advanced neuroendocrine tumors (NET) after progression on prior therapy (CABINET)
Chan, J., Geyer, S., Ou, F-S., Knopp, M., Behr, S., Zemla, T., Acoba, J., Shergill, A., Wolin, E.M., Halfdanarson, T.R., Trikalinos, N., Konda, B., Vijayvergia, N., Dasari, N.A., Strosberg, J., Kohn, E.C., Kulke, M.H., O'Reilly, E.M., Meyerhardt, J.A.
Published in Annals of oncology (01.10.2023)
Published in Annals of oncology (01.10.2023)
Get full text
Journal Article
1141O Cabozantinib versus placebo for advanced neuroendocrine tumors (NET) after progression on prior therapy (CABINET Trial/Alliance A021602): Updated results including progression free-survival (PFS) by blinded independent central review (BICR) and subgroup analyses
Chan, J., Geyer, S., Zemla, T., Knopp, M.V., Behr, S.C., Pulsipher, S., Acoba, J., Shergill, A., Wolin, E.M., Halfdanarson, T.R., Konda, B., Trikalinos, N., Shaheen, S., Vijayvergia, N., Dasari, N.A., Strosberg, J., Kohn, E.C., Kulke, M., O'Reilly, E.M., Meyerhardt, J.
Published in Annals of oncology (01.09.2024)
Published in Annals of oncology (01.09.2024)
Get full text
Journal Article
P-131 Ramucirumab and irinotecan in patients with previously treated gastroesophageal adenocarcinoma: Interim analysis of a phase II trial
Park, H., Sanjeevaiah, A., Suresh, R., Mehta, R., Trikalinos, N., Bagegni, N., Aranha, O., Pedersen, K., Nixon, A., Jin, R., Mills, J., Fields, R., Amin, M., Lim, K., Tan, B., Grierson, P., Jiang, S., Rosario, M. del, Wang-Gillam, A., Lockhart, A.
Published in Annals of oncology (01.07.2020)
Published in Annals of oncology (01.07.2020)
Get full text
Journal Article
Inconsistencies in a Study of Rifampicin-Miconazole–Impregnated Catheters versus Standard Catheters
Trikalinos, Nikolaos A., Trikalinos, Thomas A.
Published in Clinical infectious diseases (15.03.2009)
Published in Clinical infectious diseases (15.03.2009)
Get full text
Journal Article